BACKGROUND: Karyotypic abnormalities in sporadic Burkitt lymphoma (BL) have been described extensively. However, to the authors' knowledge, very limited studies have focused on the secondary chromosomal abnormalities in pediatric BL as compared with those of adult BL and on their prognostic impact. METHODS: A retrospective analysis was performed in all pediatric and adult patients at 2 institutions, with a morphologic diagnosis of BL, pretherapy tumor karyotype available, and t(8;14), t(8;22), or t(2;8) present. RESULTS: There were 33 children and 37 adults. The majority of the patients (95%) had Stage III/IV disease. There were no statistically significant differences noted in karyotype complexity and the nature of the chromosomal abnormalities between these 2 groups. Abnormalities of chromosomes 13 (13q) and 22 (22q) had a negative impact on prognosis in children. In adults, abnormalities of chromosome 17 appeared to have a negative impact. CONCLUSIONS: The current findings suggest that karyotypic information can be used for refining risk stratification in patients with BL.
BACKGROUND: Karyotypic abnormalities in sporadic Burkitt lymphoma (BL) have been described extensively. However, to the authors' knowledge, very limited studies have focused on the secondary chromosomal abnormalities in pediatric BL as compared with those of adult BL and on their prognostic impact. METHODS: A retrospective analysis was performed in all pediatric and adult patients at 2 institutions, with a morphologic diagnosis of BL, pretherapy tumor karyotype available, and t(8;14), t(8;22), or t(2;8) present. RESULTS: There were 33 children and 37 adults. The majority of the patients (95%) had Stage III/IV disease. There were no statistically significant differences noted in karyotype complexity and the nature of the chromosomal abnormalities between these 2 groups. Abnormalities of chromosomes 13 (13q) and 22 (22q) had a negative impact on prognosis in children. In adults, abnormalities of chromosome 17 appeared to have a negative impact. CONCLUSIONS: The current findings suggest that karyotypic information can be used for refining risk stratification in patients with BL.
Authors: Lisa Giulino-Roth; Kai Wang; Theresa Y MacDonald; Susan Mathew; Yifang Tam; Maureen T Cronin; Gary Palmer; Norma Lucena-Silva; Francisco Pedrosa; Marcia Pedrosa; Julie Teruya-Feldstein; Govind Bhagat; Bachir Alobeid; Lorenzo Leoncini; Cristiana Bellan; Emily Rogena; Kerice A Pinkney; Mark A Rubin; Raul C Ribeiro; Roman Yelensky; Wayne Tam; Philip J Stephens; Ethel Cesarman Journal: Blood Date: 2012-10-22 Impact factor: 22.113
Authors: Mariana Tavares de Souza; Hasmik Mkrtchyan; Rocio Hassan; Daniela Ribeiro Ney-Garcia; Alice Maria Boulhosa de Azevedo; Elaine Sobral da Costa; Amanda Faria de Figueiredo; Thomas Liehr; Eliana Abdelhay; Maria Luiza Macedo Silva Journal: Int J Hematol Date: 2011-01-05 Impact factor: 2.490
Authors: Marilu Nelson; Sherrie L Perkins; Bhavana J Dave; Peter F Coccia; Julia A Bridge; Elizabeth R Lyden; Nyla A Heerema; Mark A Lones; Lauren Harrison; Mitchell S Cairo; Warren G Sanger Journal: Br J Haematol Date: 2009-11-04 Impact factor: 6.998
Authors: Itziar Salaverria; Andreas Zettl; Silvia Beà; Elena M Hartmann; Sandeep S Dave; George W Wright; Evert-Jan Boerma; Philip M Kluin; German Ott; Wing C Chan; Dennis D Weisenburger; Armando Lopez-Guillermo; Randy D Gascoyne; Jan Delabie; Lisa M Rimsza; Rita M Braziel; Elaine S Jaffe; Louis M Staudt; Hans Konrad Müller-Hermelink; Elias Campo; Andreas Rosenwald Journal: Haematologica Date: 2008-08-12 Impact factor: 9.941